Incyclinide. Dual MMP-2/MMP-9 inhibitor treatment of acne treatment of rosacea

Drugs of the Future

Volumn 32, Issue 3, 2007, Pages 209-214

  Viera, Martha H ^a   Perez, Oliver A ^a   Berman, Brian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; ELASTASE; GELATINASE A; GELATINASE B; INCYCLINIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; METALLOPROTEINASE; PLACEBO; SERINE PROTEINASE; SUNSCREEN; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANEMIA; ANGIOGENESIS; ANOREXIA; ARTHRALGIA; ARTICLE; CARCINOGENESIS; CENTRAL NEUROTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HEARTBURN; HUMAN; IN VITRO STUDY; INFLAMMATION; KAPOSI SARCOMA; LEUKOPENIA; LUPUS LIKE SYNDROME; MALAISE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROTOXICITY; PHOTOTOXICITY; RANDOMIZED CONTROLLED TRIAL; RASH; ROSACEA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 34250310117     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.03.1083308     Document Type: Article

References (53)

1. Stephens, C.R. Jr., Conover, L.H. (Pfizer & Co., Inc.). 4-Desdimethylamino-6-deoxy-tetracycline derivatives. US 3047626.
2. Stephens, C.R., Beereboom, J.J., Rennhard, H.H., Gordon, P.N., Murai, K., Blackwood, R.K., Schach Von Wittenau, M. 6-Deoxytetracyclines. IV. Preparation, C-6 stereochemistry, and reactions. J Am Chem Soc 1963, 85(17): 2643-52.
3. Beereboom, J.J., Butler, K. (Pfizer & Co., Inc.). Hydrolysis of 2-decarboxamido-2-cyano-6-deoxy-tetracycline derivatives. US 3069467.
4. Golub, L., McNamara, T., D'Angelo, A., Greenwald, R., Ramamurthy, S. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. Dent Res 1987, 66: 1310-4.
5. Golub, L., Lee, H., Lehrer, G. Minocycline reduces gingival collagenolytic activity during diabetes: Preliminary observations and a proposed new mechanism of action. J Periodont Res 1983, 18: 516-26.
6. Golub, L., Ramamurthy, S., McNamara, T. et al. Tetracyclines inhibit tissue collagenase activity: A new mechanism in the treatment of periodontal disease. J Periodont Res 1984, 19: 651-5.
7. Maitra, S.R., Shapiro, M.J., Bhaduri, S., El-Maghrabi, M.R. Effect of chemically modified tetracycline on transforming growth factor-beta1 and caspase-3 activation in liver of septic rats. Crit Care Med 2005, 33: 1577-81.
8. Golub, L., Ramamurthy, N., McNamara, T. Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991, 2: 297-321.
9. Sapadin, A.N., Fleischmajer, R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006, 54: 258-65.
10. Sandler, C., Ekokoski, E., Lindstedt, K.A. et al. Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: Possible involvement of protein kinase C. Inflamm Res 2005, 54: 304-12.
11. Gu, Y., Lee, H.M., Golub, L.M., Sorsa, T., Konttinen, Y.T., Simon, S.R. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Ann Med 2005, 37: 450-60.
12. Steinberg, J., Halter, J., Schiller, H. et al. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock 2005, 24: 348-56.
13. Kim, J.H., Lee, S.Y., Bak, S.M. et al. Effects of matrix metalloproteinase inhibitor on LPS-induced goblet cell metaplasia. Am J Physiol Lung Cell Mol Physiol 2004, 287: L127-33.
14. Hidalgo, M., Eckhardt, S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001, 93: 178-93.
15. Li, J., Zhou, S., Huynh, H., Chan, E. Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. Pharm Res 2005, 22: 397-404.
16. Li, J., Zhou, S., Huynh, H., Duan, W., Chan, E. Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin. Pharm Res 2005, 22: 1954-63.
17. Syed, S., Takimoto, C., Hidalgo, M. et al. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 2004, 10: 6512-21.
18. Cianfrocca, M., Cooley, T.P., Lee, J.Y. et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS Malignancy Consortium study. J Clin Oncol 2002, 20: 153-9.
19. Rudek, M.A., Figg, W.D., Dyer, V. et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001, 19: 584-92.
20. Rudek, M.A., Venitz, J., Ando, Y., Reed, E., Pluda, J.M., Figg, W.D. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: Clinical and experimental studies. J Clin Pharmacol 2003, 43: 1124-35.
21. Carney, D.E., McCann, U.G., Schiller, H.J. et al. Metalloproteinase inhibition prevents acute respiratory distress syndrome. J Surg Res 2001, 99: 245-52.
22. Ghate, J.V., Turner, M.L., Rudek, M.A. et al. Drug-induced lupus associated with COL-3: Report of 3 cases. Arch Dermatol 2001, 137: 471-4.
23. Eklund, K.K., Sorsa, T. Tetracycline derivative CMT-3 inhibits cytokine production, degranulation, and proliferation in cultured mouse and human mast cells. Ann NY Acad Sci 1999, 878: 689-91.
24. Maitra, S.R., Bhaduri, S., Valane, P.D., Tervahartiala, T., Sorsa, T., Ramamurthy, N. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock 2003, 20: 280-5.
25. Maisi, P., Kiili, M., Raulo, S.M., Pirila, E., Sorsa, T. MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid. Ann NY Acad Sci 1999, 878: 675-77.
26. Steinger, J., Halter, J., Schiller, H. et al. Metalloproteinases inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. Surg Res 2003, 111: 185-95.
27. Muir, P., Manley, P.A., Hao, Z. COL-3 inhibition of collagen fragmentation in ruptured cranial cruciate ligament explants from dogs with stifle arthritis. Vet J 2006, Epub ahead of print.
28. Fife, R.S., Sledge, G.W. Jr., Sissons, S., Zerler, B. Effects of tetracyclines on angiogenesis in vitro. Cancer Lett 2000, 153: 75-8.
29. Gu, Y., Lee, H.M., Roemer, E.J., Musacchia, L., Golub, L.M., Simon, S.R. Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem 2001, 8: 261-70.
30. Lokeshwar, B.L., Houston-Clark, H.L., Selzer, M.G., Block, N.L., Golub, L.M. Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer. Adv Dent Res 1998, 12: 97-102.
31. Lokeshwar, B.L. MMP inhibition in prostate cancer. Ann NY Acad Sci 1999, 878: 271-89.
32. Lokeshwar, B.L., Selzer, M.G., Zhu, B.Q., Block, N.L., Golub, L.M. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002, 98: 297-309.
33. Selzer, M.G., Zhu, B., Block, N.L., Lokeshwar, B.L. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer. Ann NY Acad Sci 1999, 878: 678-82.
34. Seftor, R.E., Seftor, E.A., Kirschmann, D.A., Hendrix, M.J. Targeting the tumor microenvironment with chemically modified tetracyclines: Inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 2002, 1: 1173-9.
35. Seftor, R.E., Seftor, E.A., De Larco, J.E. et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 1998, 16: 217-25.
36. Saikali, Z., Singh, G. Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs 2003, 14: 773-8.
37. Liu, Y., Ryan, M.E., Lee, H.M. et al. A chemically modified tetracycline (CMT-3) is a new antifungal agent. Antimicrob Agents Chemother 2002, 46: 1447-54.
38. Onoda, T., Ono, T., Dhar, D.K., Yamanoi, A., Nagasue, N. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer 2006, 118: 1309-15.
39. Chen, J., Bookbinder, M., Ryan, M.E., Golub, L.M., Ashley, R., Ramamurthy, N.S. Biodistribution of radiolabeled [(3)H] CMT-3 in rats. Curr Med Chem 2001, 8: 253-6.
40. Li, J., Huynh, H., Chan, E. Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration. Pharm Res 2002, 19: 1655-62.
41. CollaGenex Pharmaceuticals reports positive outcome of phase 2 clinical study evaluating COL-3 as a treatment for rosacea. CollaGenex Pharmaceuticals, Inc. Press Release, April 15, 2005.
42. Positive results of CollaGenex Pharmaceuticals' phase 2 clinical study evaluating effects of COL-3 for treating rosacea presented at North Carolina Dermatology Association. CollaGenex Pharmaceuticals, Inc. Press Release, August 2, 2005.
43. CollaGenex Pharmaceuticals initiates phase 2 clinical trial to evaluate incyclinide (COL-3) for the treatment of acne. CollaGenex Pharmaceuticals, Inc. Press Release, September 26, 2005.
44. CollaGenex Pharmaceuticals announces positive results of phase 2 dose-finding study of incyclinide for the treatment of acne. CollaGenex Pharmaceuticals, Inc. Press Release, March 1, 2007.
45. Acharya, M.R., Venitz, J., Figg, W.D., Sparreboom, A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat 2004, 7: 195-208.
46. Furlow, B. COL-3 benefits patients with AIDS-related Kaposi's sarcoma. Lancet Oncol 2006, 7: 368.
47. McGarvey, M.E., Tulpule, A., Cai, J. et al. Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. Curr Opin Oncol 1998, 10: 413-21.
48. Rawal, S.Y., Rawal, Y.B. Non-antimicrobial properties of tetracyclines - Dental and medical implications. West Indian Med J 2001, 50: 105-8.
49. Chemotherapy in treating patients with advanced solid tumors (NCT00003721). ClinicalTrials.gov Web site, February 20, 2007.
50. COL-3 in treating patients with HIV-related Kaposi's sacoma (NCT00020683). ClinicalTrials.gov Web site, February 20, 2007.
51. A phase I study of oral COL-3 (NSC-683551), a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer (NCT00001683). ClinicalTrials.gov Web site, February 20, 2007.
52. COL-3 in treating patients with progressive or recurrent brain tumors (NCT00004147). ClinicalTrials.gov Web site, February 20, 2007.
53. Dezube, B.J., Krown, S.E., Lee, J.Y., Bauer, K.S., Aboulafia, D.M. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS Malignancy Consortium study. J Clin Oncol 2006, 24: 1389-94.